PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för mirabegron. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

13 hits

Bibliografisk träff 2012-07-01

Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction.

Gillespie JI, Palea S, Guilloteau V, Guerard M, Lluel P, Korstanje C.

BJU Int · research support, non-u.s. gov't; journal article · DOI 10.1111/j.1464-410x.2012.11240.x

Bibliografisk träff 2012-07-01

Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction.

Wyndaele JJ.

BJU Int · comment; editorial · DOI 10.1111/j.1464-410x.2012.11259.x

Bibliografisk träff 2012-05-01

[Pharmacological and clinical profile of mirabegron (Betanis(®)): a new therapeutic agent for overactive bladder].

Suzuki M, Ukai M, Sasamata M, Seki N.

Nihon Yakurigaku Zasshi · review; journal article · DOI 10.1254/fpj.139.219

Bibliografisk träff 2012-05-01

Treatment of overactive bladder symptoms beyond antimuscarinics: current and future therapies.

Ellsworth P.

Postgrad Med · review; journal article · DOI 10.3810/pgm.2012.05.2544

Bibliografisk träff 2012-04-18

Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β3-adrenoceptor agonist.

Takusagawa S, Yajima K, Miyashita A, Uehara S, Iwatsubo T, Usui T.

Xenobiotica · journal article · DOI 10.3109/00498254.2012.675095

Bibliografisk träff 2012-03-13

Use of mirabegron in treating overactive bladder.

Bhide AA, Digesu GA, Fernando R, Khullar V.

Int Urogynecol J · review; journal article · DOI 10.1007/s00192-012-1724-0

Bibliografisk träff 2012-03-10

An aryloxypropanolamine hβ3-adrenoceptor agonist as bladder smooth muscle relaxant.

Tasler S, Baumgartner R, Behr-Roussel D, Oger-Roussel S, Gorny D, Giuliano F, Ney P.

Eur J Pharm Sci · comparative study; journal article · DOI 10.1016/j.ejps.2012.03.001

Bibliografisk träff 2012-01-26

Development and validation of LC-MS/MS methods for the determination of mirabegron and its metabolites in human plasma and their application to a clinical pharmacokinetic study.

Teijlingen Rv, Meijer J, Takusagawa S, Gelderen Mv, Beld Cv, Usui T.

J Chromatogr B Analyt Technol Biomed Life Sci · research support, non-u.s. gov't; journal article · DOI 10.1016/j.jchromb.2012.01.018

Bibliografisk träff 2012-01-23

Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.

Takusagawa S, van Lier JJ, Suzuki K, Nagata M, Meijer J, Krauwinkel W, Schaddelee M, Sekiguchi M, Miyashita A, Iwatsubo T, van Gelderen M, Usui T.

Drug Metab Dispos · clinical trial; research support, non-u.s. gov't; journal article · DOI 10.1124/dmd.111.043588

Bibliografisk träff 2012-01-01

Mirabegron for the treatment of overactive bladder.

Gras J.

Drugs Today (Barc) · journal article · DOI 10.1358/dot.2012.48.1.1738056

Bibliografisk träff 2011-04-12

β-adrenoceptor agonist effects in experimental models of bladder dysfunction.

Michel MC, Ochodnicky P, Homma Y, Igawa Y.

Pharmacol Ther · research support, non-u.s. gov't; review; journal article · DOI 10.1016/j.pharmthera.2011.03.014

Bibliografisk träff 2010-12-09

Mirabegron: a safety review.

Tyagi P, Tyagi V, Chancellor M.

Expert Opin Drug Saf · review; journal article · DOI 10.1517/14740338.2011.542146

Bibliografisk träff 2010-10-01

Mirabegron, a β₃-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder.

Tyagi P, Tyagi V.

IDrugs · review; journal article